PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
96.69%
Cash & equivalents yoy growth at least 1.5x CRVO's 56.98%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
96.69%
Cash + STI yoy ≥ 1.5x CRVO's 56.98%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.86%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
94.31%
≥ 1.5x CRVO's 47.40%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-6.34%
0.5-0.75x CRVO's -8.66%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
≥ 1.5x CRVO's -0.88%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
78.33%
≥ 1.5x CRVO's 18.40%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-11.61%
Less than half of CRVO's 1.90%. David Dodd sees a more disciplined AP approach or lower volume.
-42.55%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
11.61%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-11.56%
Similar yoy to CRVO's -12.60%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.36%
1.25-1.5x CRVO's -7.12%. Martin Whitman is wary of heavier future burdens.
No Data
No Data available this quarter, please select a different quarter.
-11.23%
1.1-1.25x CRVO's -9.28%. Bill Ackman questions if the firm is incurring more total obligations than competitor.
36.01%
Similar yoy changes to CRVO's 39.00%. Walter Schloss sees parallel capital-raising strategies.
-2.61%
0.75-0.9x CRVO's -3.02%. Bill Ackman questions if competitor reinvests profits more robustly.
-6.95%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
193.87%
≥ 1.5x CRVO's 24.88%. David Dodd sees stronger capital base growth than competitor.
78.33%
≥ 1.5x CRVO's 18.40%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.95%
1.25-1.5x CRVO's -6.87%. Martin Whitman is wary of bigger debt expansions vs. competitor.
-116.79%
Above 1.5x CRVO's -60.96%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.